Last reviewed · How we verify
Quadrivalent High-dose Influenza Vaccine
Quadrivalent High-dose Influenza Vaccine is a Influenza vaccine Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 3 development for Prevention of influenza disease in adults 65 years of age and older.
This vaccine induces an immune response against multiple influenza strains.
This vaccine induces an immune response against multiple influenza strains. Used for Prevention of influenza disease in adults 65 years of age and older.
At a glance
| Generic name | Quadrivalent High-dose Influenza Vaccine |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The quadrivalent high-dose influenza vaccine contains antigens from four different influenza strains, which stimulate the body's immune system to produce antibodies that can recognize and neutralize these viruses. This immune response helps to protect against influenza infection and its associated complications.
Approved indications
- Prevention of influenza disease in adults 65 years of age and older
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
- Muscle pain
- Fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent High-dose Influenza Vaccine CI brief — competitive landscape report
- Quadrivalent High-dose Influenza Vaccine updates RSS · CI watch RSS
- Janssen Vaccines & Prevention B.V. portfolio CI
Frequently asked questions about Quadrivalent High-dose Influenza Vaccine
What is Quadrivalent High-dose Influenza Vaccine?
How does Quadrivalent High-dose Influenza Vaccine work?
What is Quadrivalent High-dose Influenza Vaccine used for?
Who makes Quadrivalent High-dose Influenza Vaccine?
What drug class is Quadrivalent High-dose Influenza Vaccine in?
What development phase is Quadrivalent High-dose Influenza Vaccine in?
What are the side effects of Quadrivalent High-dose Influenza Vaccine?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: Janssen Vaccines & Prevention B.V. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of influenza disease in adults 65 years of age and older
- Compare: Quadrivalent High-dose Influenza Vaccine vs similar drugs
- Pricing: Quadrivalent High-dose Influenza Vaccine cost, discount & access